In short:
Far North Queensland couple are part of a team leading early research using naturally occurring antibodies to specifically target and treat the underlying cause of type 1 diabetes.
asserted
couple → lead → diabetes
In one trial on mice, 80 per cent responded to treatment.
asserted
cent → respond → treatment
The team will need to secure FDA clearance before moving into human trials.
asserted
team → need → trials
A Far North Queensland couple who started their research journey in Cairns are behind "promising" early research on a new type 1 diabetes treatment.
asserted
who → start → treatment
Rafid Al-Hallaf and his wife, Zainab Agha, migrated to Cairns in 2013 to study immunology at James Cook University (JCU).
asserted
Hallaf → migrate → University
More than a decade later, they are part of new research published in the Journal of Immunology from Johns Hopkins University (JHU) in America targeting type 1 diabetes.
asserted
they → publish → diabetes
According to Diabetes Australia, about 134,000 Australians are currently living with type 1 diabetes, an autoimmune condition.
uncertain
Australians → accord → diabetes
Current treatment replaces the insulin that the body can no longer make.
asserted
body → replace → that
"Our approach is different because we are trying to treat the cause of the disease, which is the autoimmune attack," Dr Al-Hallaf said.
asserted
Hallaf → try → disease
"Rather than simply replacing the insulin, we are trying to stop the immune system from destroying the cell that produces it.
asserted
that → replace → it
"
What did they discover?
During an immune response like diabetes, the immune system produces a variety of antibodies, including some that scientists do not fully understand.
asserted
scientists → discover → that
JHU scientists, led by Abdel-Rahim Hamad, found immune cells from type 1 diabetes patients were making a specific, previously unrecognised antibody, dubbed "x-mAb".
asserted
cells → lead → antibody
Dr Hamad said current immunotherapy treatment worked "like a sledgehammer", suppressing large parts of the immune system and leaving patients vulnerable to infections.
asserted
treatment → say → infections
However, he said the x-mAb antibody worked like a "guided missile".
asserted
antibody → say → missile
"It selectively disarms only the rogue T cells destroying the pancreas, leaving the rest of your immune defence fully functional."
In a trial on mice in the early stages of type 1 diabetes, 16 were treated with the antibody and five with a placebo.
asserted
16 → disarm → placebo
All 16 mice had their blood sugar return to normal levels, while none of the placebo mice went into remission.
asserted
none → have → remission
In another experiment of pre-diabetic mice, 10 received the antibody and 10 received a placebo.
asserted
10 → receive → placebo
About 70 per cent of those treated mice then stayed disease-free for the rest of the three-month study.
asserted
cent → treat → study
"This is really, really promising," Dr Al-Hallaf said.
asserted
Hallaf → say → ?
'Holy grail' of treatment
St Vincent's Institute immunologist Tom Kay, who is not involved in the research, said it had promising results.
asserted
it → involve → results
"It's a creative and out-of-left-field idea that I think brings new ideas to the field," Professor Kay said.
asserted
Kay → think → field
He said scientists had long chased precisely that kind of highly targeted treatment.
asserted
scientists → say → treatment
"It's a holy grail in treating autoimmunity that you're trying to make the treatment as specific as possible,"he said.
asserted
treatment → treat → autoimmunity
Professor Kay said the earlier a patient was treated after diagnosis, the more of their own insulin production could be preserved.
His own team had worked on identifying a key driver of the autoimmune attack in type 1 diabetes and trialled an existing rheumatoid arthritis drug, baricitinib, in newly diagnosed patients.
Unlike x-mAb, which aims to precisely target only the specific rogue immune cells, the St Vincent's Institute's drug blocked the whole immune-signalling pathway driving the disease.
uncertain
drug → say → disease
However, Professor Kay said there were limitations in how short the JHU mouse trials were and he would have liked to see them carried out longer to see if the drug had a lasting impact.
asserted
drug → say → impact
He said he would closely watch the research as it moved from mice towards possible human trials.
asserted
it → say → trials
To undertake human trials, the JHU team will first need clearance from the US Food and Drug Administration (FDA).
asserted
team → undertake → Administration
"You're talking about definitely a decade, probably more, to go from successful mouse studies to the end of clinical trials," Professor Kay said.
asserted
Kay → talk → trials
Home in Cairns
As the research moves forward, Dr Al-Hallaf said his family ultimately wanted to return to Cairns where they still own a home.
asserted
they → move → home
He hopes the JHU discovery could help treat skin cancer in Far North Queensland, where some of the highest rates occur.
uncertain
some → hop → rates
"We want to further characterise these cells … to see if this antibody can also have an impact on animals that have cancer," he said.
asserted
he → want → cancer
"The ultimate goal is to establish my own lab back in JCU and hopefully we'll try to bring this expertise."
asserted
we → establish → expertise
The Aporia